Remyelination therapies are an emerging approach for treating multiple sclerosis, but development of these therapies is hampered by a lack of imaging biomarkers. Imaging with improved specificity to myelin, as compared to conventional MRI, have the potential to act as biomarkers, but current implementations can be time consuming. We examine the performance of fast version of myelin imaging from the perspective of reproducibility, a necessary prerequisite for use in proof-of-concept clinical trials of remyelinating agents.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords